Skip to content

8:50 am Chair’s Opening Remarks

  • Christina Bender Exploratory Biomarker & Oncology Commercialization Lead, Bristol-Myers Squibb

Harnessing Improved Technologies to Advance the Industry Applications of Liquid Biopsy

9:00 am What’s New? An Overview of the Liquid Biopsy Space


• Uncovering the latest advancements, challenges and strategies seen across the liquid biopsy field

• Discussing the current state of play on clinical use and uptake of liquid biopsies: How do we advance this even further?

• Where next? Taking a look into what’s on the horizon for non-invasive tests and key next steps for drug developers

9:30 am Accurate Biomarker Identification Through Digital Sequencing: Accelerating Adoption of ctDNA in Trials & the Clinic

  • Kimberly Banks Senior Director, Medical Affairs, BioPharma , Guardant Health


• Lessons from 100,000 patients to improve assay performance

• Clinical trial case studies for faster enrollment and study insights

• Improving patient treatment and outcomes

10:00 am Panel Discussion: Women in Precision Medicine


Coming soon. Uniting scientific and business leaders from all key stakeholders of the community, this keynote panel discussion will highlight the importance of a diverse workforce and provide actionable takeaways for increased advocacy in individual workplaces. Stay tuned!

10:45 am Speed Networking

11:10 am Morning Refreshments

11:30 am Bridging the GAP in Liquid Biopsies — CTCs & cfDNA: A Comprehensive Approach to Detection & Monitoring of Cancer


• Cancer is a high complexity disease which requires a combination of biological insights from both genotypic and phenotypic analysis to guide precision medicine
• Circulating tumor cells (CTCs) and cell free DNA (cfDNA) liquid biopsies enable complementary information for clinical decisions, allowing for diagnosis, accurate prognosis, therapeutic target selection, as well as monitoring response and resistance to treatment
• Find out how these technologies enable a true Comprehensive Cancer Profiling from a single tube of blood to get all the biological insights needed

12:00 pm Novel Digital PCR & Mutation Enrichment Technologies for the Analysis of Clinically Relevant DNA Alterations in Liquid Biopsies


• With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable

• We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis

• Application in circulating DNA from clinical cancer samples will be presented

12:30 pm Extracellular Vesicles in Disease Monitoring: Evaluating a New Analyte Approach for Liquid Biopsy


• Understanding the advantage of extracellular vesicles as a diagnostic and prognostic tool for certain applications

• Strategies to maximize marker detection from extracellular vesicles through purification and analysis techniques

• How are extracellular vesicles being applied? Evaluating the safety, predictive and diagnostic markers

1:00 pm

Networking Lunch

Addressing Pre-Analytical Steps to Maximize Reliability of Trials & Ensure Quality Sample Management

2:00 pm Leveraging Liquid Biopsies in Clinical Development Across a Portfolio


• Finding the specific driver of disease to inform target identification

• Overcoming key challenges in translation to clinical trials

• Exploring sensitivity levels required for biomarker and analyte types across a portfolio

2:30 pm Exploiting RNA in Liquid Biopsies for Precision Medicine Purposes

  • Jo Vandesompele Professor & Chief Scientific Officer , Ghent University & Biogazelle


• Biofluids are rich sources of messenger RNA, circular RNA and microRNAs

• The Human Biofluid RNA Atlas: a novel compendium of human extracellular transcriptomes

• The Extracellular RNA Quality Control study: benchmarking plasma RNA transcriptome profiling

3:00 pm Afternoon Refreshments

3:30 pm The Impact of Matrix Selection as a Pre-Analytical Variable on BloodBased Protein Biomarker Quantification

  • Leighla Tayefeh Research Associate, Biomarker Development , Ionis Pharmaceuticals


• In the context of protein biomarkers measurements, the goal is to measure the levels that are circulating

• Understanding the impact of proper sample matrix selection is an important piece of this. Platelets and other circulating cells can release proteins during the process of coagulation

• Anticoagulants can affect the ability to detect different proteins. If the proper matrix is not selected the measurements may be incorrect

4:00 pm BloodPAC Data Common: Accelerating Data Sharing & Analysis


• Exploring the BloodPAC Data Common and its applications in liquid biopsy-based studies

• Heading for approval: Demostrating how having an FDA approved Data Common positively impacts your future studies

• Looking ahead to future directions and applications of the project

4:30 pm Panel Discussion

  • Benoit Destenaves Director & Precision Medicine Lead , AstraZeneca
  • Hua Fang Clinical Biomarker Lead, ImmunoOncology, Oncology Early Clinical Development , AbbVie


• Tackling assay validation and ensuring markers are clinically applicable for expedited drug development

• Finding the specific driver of disease: How far can current technologies take us?

• Cost vs quality: Avoiding false positives by finding the right, cost-effective technology for your biomarker

5:15 pm Chair’s Closing Remarks & End of Day One

  • Christina Bender Exploratory Biomarker & Oncology Commercialization Lead, Bristol-Myers Squibb